Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Can ICE agents detain U.S. citizens? What powers do they have to arrest people? Your most common questions answered. - 2Step by step instructions to Keep up with Great Hand Cleanliness Before Handshakes
- 3What’s your chronotype? Knowing whether you’re a night owl or an early bird could help you do better on tests and avoid scams
- 4The 2026 'Super Bowl of Astronomy' starts today — here's what's happening
- 5Consumer experts: German petrol hikes rule won't bring down prices
- I’m a dad to an autistic child. Here’s how you can make the holidays easier for all of us.
- 5 Great Home Remodel Administrations With Green Arrangements In 2024
- Day to day Temporary Positions That Compensate Fairly in the US
- 6 Novice Cameras for 2024: Ideal for New Picture takers
- Poll: 62% of Americans would oppose U.S. military action in Greenland
- Misjudged Objections For Solo Voyagers
- The Most Notable Design Brands of the 21st Hundred years
- Sean 'Diddy' Combs faces new sexual assault allegations, currently under investigation by Los Angeles Sheriff's Department
- Are your hormones imbalanced? Doctors explain how to know if you need testing
